Skip to content

A comparison of the effects of the putative 5HT1A antagonist MM-77 with WAY-100635 on the mouse isolated vasa deferentia

Research output: Contribution to journalArticlepeer-review

  • M. Arkle
  • Stephen Arkle
  • Ivor Ebenezer
1-(2-methoxyphenyl)-4-(4-succinimidobutyl) piperazine (MM-77) is a putative 5-HT1A antagonist with apparent specificity for postsynaptic 5HT1A receptors (Mokrosz et al., 1994). However, we have reported that MM-77 displays some characteristics of a 5-HT1A agonist and an adrenoceptor antagonist (Arkle et al., 2004). The mouse vas deferens has a high density of adrenergic receptors (Kitchen, 1984) and our preliminary experiments showed that MM-77 produces concentration-dependent inhibition of contractile responses to submaximal electrical field stimulation, indicative of adrenergic inhibition. To further characterise this effect, we compared the effects of MM-77 and the selective 5-HT1A antagonist WAY100635 (Fletcher et al., 1996) on phenylephrine (PE)-stimulated contractions of mouse isolated vas deferens. Adult male CFLP mice (b. wt. ~50g) were killed by exposure to CO2 and cervical dislocation. Vasa deferentia were mounted in 15 ml organ baths in Krebs Ringer for isometric recording (Kitchen, 1984), incubated with 10-7-10-6M MM-77 or WAY-100635 and then sequentially exposed to 10-6–10-3M PE for 30s in a 3 min time cycle Schild plots were constructed from these data with dose ratios calculated at 25% of tissue maximal response (Emax). MM-77 produced a rightward shift of concentration-responses curves to PE with a progressive decrease in Emax (fig.1). Schild plots of these data were linear with a mean intercept of -6.8 ± 0.1 and slope of 1.42 ± 0.2, consistent with non-competitive antagonism at 1 -adrenoceptors. By contrast, while WAY-100635 also caused a rightward shift of the PE concentration-response curves, there was no loss of Emax except at the 1 μM concentration (fig. 2). Schild plots of these data were linear with a mean intercept of -7.1±0.1 and slope of 1.0±0.1, consistent with competitive 1-adrenoceptor antagonism. WAY-100635 has a 10 fold greater potency than MM-77 in vivo and this may explain the overt adrenergic antagonistic effects that we reported with MM-77 in behavioural studies (Arkle et al., 2004). Nevertheless, the action of these drugs at -adrenoceptors may confound interpretation of selective 5-HT1A receptor effects in behavioural experiments.
Original languageEnglish
JournalpA2 online
Publication statusPublished - Jul 2004

Related information

Relations Get citation (various referencing formats)

ID: 164301